84 results about "Psychiatric Disease" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention relates to the technical field of psychiatric disease diagnosis, and discloses a defective schizophrenia prediction and analysis system based on multi-modal brain network characteristics, which comprises an image data acquisition module, an image data processing module, a deep learning model module and a prediction module which are connected in sequence, the image data acquisition module acquires a brain MRI image; the image data processing module carries out cortical and subcortical reconstruction on the brain MRI image to obtain a model input index; the deep learning model module performs training by using a training data set composed of a plurality of brain MRI images and defective schizophrenia diagnosis results thereof to obtain a target prediction model; and the prediction module inputs the real-time brain MRI image into the target prediction model to obtain a prediction result. According to the method, the multi-dimensional brain structure image features are integrated, diagnosis information contained in brain region changes is fully mined, prediction results of defective schizophrenia and non-defective schizophrenia are improved, and a more comprehensive biological basis is provided for clinical diagnosis.

There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.

The present disclosure provides azocino[4,5,6-cd]indoles as serotonin receptor modulators. Uses of said compounds in the treatment of medical disorders, such as neurological or psychiatric disorders, and processes of synthesizing said compounds are also provided.

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

The invention establishes a rapid, accurate and efficient high performance liquid chromatography-mass spectrometry detection method for detecting the common antipsychotic drugs in the hair, and the concentration of ten common antipsychotic drugs or metabolites in the hair can be quantitatively detected at the same time; the method is suitable for clinical blood concentration monitoring, drug poisoning screening and large-scale biological sample detection, and has very significant significance in clinical use.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

Provided are methods of treating a neurological or psychiatric disease or disorder, methods of treating behavioral problems associated with a neurological or psychiatric disease or disorder, and methods of improving behavioral and / or psychological symptoms of a neurological or psychiatric disease or disorder in a subject in need thereof.

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

The present invention relates to macrocyclic FKBP51-binding compounds having improved characteristics, as well as solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and / or diluents. Said compounds have been identified as especially potent ligands of FK506 binding proteins (FKBPs also called MIPs in bacteria), especially human FKBP51 and are useful for treatment of diseases such as psychiatric, metabolic and neurological disorders as well as pain and cancers. Said substituted derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues (FIG. 10).

The invention discloses a composition, a method and a system for predicting the applicability of antipsychotic drugs. The invention develops a composition, a detection kit, a model construction method and a system for predicting the applicability of antipsychotic drugs on the basis of selected SNP site information. Particularly, a gene marker combination related to the curative effects of the antipsychotic drugs olanzapine, risperidone, aripiprazole and quetiapine is found by adopting a large-sample high-throughput whole-genome association analysis technology, and a corresponding mathematical model for predicting the curative effects is constructed; the model can be used for predicting the PANSS subtraction rate after the schizophrenia is treated by medication based on DNA polymorphic sites and clinical basic information of a medication user in a high, medium and low classification manner, and assists in guiding the selection of the types of the medication, so that personalized treatment of the schizophrenia patient is realized.

The present invention relates to novel compounds of Formula (I), (I), wherein P, Q, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which GABAB-R is involved.

Disclosed in the present invention is a wearable psychiatric patient restraint apparatus, relating to the technical field of psychiatric patient care apparatuses. The wearable psychiatric patient restraint apparatus comprises an apparatus main body and a restraint strap. A sliding block is movably mounted at the top end of the apparatus main body, and a restraint mechanism is disposed between a pulley block and the sliding block. A protective pad is fixedly mounted on an inner side surface of the restraint strap, a moving block is movably mounted on an inner side surface of the apparatus main body, and an adjustment mechanism is disposed between the protective pad and the moving block. According to the wearable psychiatric patient restraint apparatus, a drive motor works to drive a drive shaft to drive a spiral member to rotate, and the spiral member drives the sliding block to drive a support plate to move, so that the position of the restraint strap is conveniently adjusted, a patient is conveniently restrained at a comfortable position, and the psychological pressure of the patient is reduced, thereby making it convenient for the nursing staff to dress a patient. Moreover, the protective pad on the inner side of the restraint strap is used for protecting the wrists and ankles of the psychiatric patient, thereby reducing the wear of the wrists and ankles of the patient.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The utility model relates to a massage cap for psychiatric patients, which belongs to the field of auxiliary treatment equipment for psychiatric patients and comprises an upper fixing column, a lower fixing ring, a massage head component and a massage head fixing piece. The lower fixing ring comprises adjusting rods provided with sliding grooves A and a sleeve connected between the adjusting rods, a fixing rod is arranged in the sleeve, the two ends of the fixing rod are connected with springs respectively, and the two adjusting rods adjacent to the sleeve are inserted into the sleeve respectively and connected with the springs; a sliding groove B is formed in the outer wall of the upper fixing column; sliding blocks matched with the sliding grooves B and the sliding grooves A are arranged at the upper end and the lower end of the massage head fixing piece respectively, and the massage head fixing piece is slidably connected between the upper fixing column and the lower fixing ring through the sliding blocks. A sliding groove C is formed in the middle of the massage head fixing piece, and the massage head assembly is connected into the sliding groove C in a sliding mode. The mental patient massage device can be suitable for being worn by patients with different head circumferences, the position of the massage head can be adjusted according to symptoms of different mental patients, and the treatment effect is enhanced.

The invention relates to the technical field of psychiatric medical equipment, and discloses a mental patient medicine taking intelligent checking system and method based on an image recognition technology. The system comprises a facial feature acquisition module, a medicine identification module, a medicine taking action capture module, a data fusion module, a medicine taking compliance analysis module, an abnormal behavior identification module, an intervention instruction generation module, a medical care alarm module and a medicine taking record updating module. The medicine recognition module generates medicine contour feature points to check medicines; the medicine taking action capture module captures hand movement tracks; the data fusion module aligns the three parts in a space-time manner; the medicine taking compliance analysis module compares action compliance; the abnormal behavior recognition module recognizes abnormal swallowing actions, the intervention instruction generation module generates grading intervention signals, the medical care alarm module triggers corresponding alarms, and the medicine taking record updating module updates the electronic medicine taking archive when medicine taking is compliant.

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.

The invention discloses a closestool with a safety protection structure for mental patients, and relates to the technical field of closestools. The toilet bowl with the safety protection structure for the mental patient comprises a toilet bowl body and a seat erected on the toilet bowl body, the seat comprises a main body and handrails fixedly connected to the two sides of the main body, a flexible check curtain for shielding or opening a through groove is arranged in the main body, and a restraining mechanism is jointly installed on the main body and the handrails; the seat is erected on the closestool, and the slidable flexible check curtain is arranged in the seat, so that when a mental patient is dazzling and likely to catch excrement to throw, the flexible check curtain can be pushed to quickly close the through groove, and then the upper part of the closestool is sealed; meanwhile, the restraint mechanism is arranged on the seat, when the patient has a mad sign, the patient can be pressed, the restraint mechanism can be quickly started to contract, the upper body of the patient is bound on the main body through the restraint strap, the patient cannot get up, and further control is facilitated for medical staff.

The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

This invention discloses a method and apparatus for generating personalized data sources for assisting in decision-making regarding electrical stimulation protocols. Belonging to the field of biomedical engineering technology, it acquires high-precision EEG signals and medical record text information from patients and preprocesses them to obtain multimodal feature vectors. These multimodal feature vectors are then used for RAG medical knowledge retrieval and multi-agent cross-validation to identify characteristic EEG indicators of neurological / psychiatric diseases, revealing abnormal brain regions. Based on these abnormal brain region results, a personalized data source is generated to assist in decision-making regarding electrical stimulation protocols. This assists decision-makers in making informed decisions, providing objective diagnostic evidence for various neurological / psychiatric diseases and overcoming excessive reliance on doctors' subjective experience.

Disclosed are compounds of formula (I):and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Provided are methods of treating a neurological or psychiatric disease or disorder, methods of treating behavioral problems associated with a neurological or psychiatric disease or disorder, and methods of improving behavioral and / or psychological symptoms of a neurological or psychiatric disease or disorder in a subject in need thereof.

This application relates to the field of physiological function assessment technology, and in particular to a method and system for assessing swallowing function in psychiatric patients based on multidimensional physiological signals. The method includes: S1, acquiring basic information and medication information of the psychiatric patient to be assessed, and collecting multidimensional physiological signals; S2, extracting swallowing feature vectors based on these signals; S3, identifying behavioral risks in psychiatry based on swallowing event sequences and inertial measurement signals, obtaining behavioral risk labels and their confidence levels; S4, extracting extrapyramidal response representation vectors based on multidimensional physiological signals, and outputting the probability of swallowing difficulties related to extrapyramidal responses through a pre-set classification model; S5, mapping different abnormal indicators to item scores for nursing risk assessment items, obtaining a total score; S6, generating an assessment report containing item scores, total score, risk level, and key physiological evidence. This application solves the problem that existing assessments rely on subjective observation and lack objective evidence support.

The present disclosure provides pharmaceutical compositions for subcutaneous administration comprising olanzapine, an organic solvent, and a triblock copolymer and a diblock copolymer, and methods of treating psychiatric diseases and disorders using such compositions.

The present invention provides use of 2-hydroxy-4-(2-hydroxy-3,5-dichlorobenzyl)aminobenzoic acid 2-camphol ester in the preparation of a drug for treating psychiatric diseases. The novel drug for treating psychiatric diseases provided by the present invention may play a role in regulating the imbalance in the excitation / inhibition of a neural circuit by means of mechanisms such as targeted nNOS-PSD95 uncoupling and the agonistic effect of the α2 GABA A receptor, and has a significant inhibitory effect on immune inflammation, which plays an important role in the development and progression of psychiatric diseases. The novel drug provided by the present invention further inhibits central inflammation on the basis of regulating the imbalance in the excitation / inhibition of a central neural circuit.